In this second segment of Bob Proulx’s presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be used in cancer medicine. This video introduces roles for magnetic relaxometry in early cancer detection, cancer staging, and therapeutic monitoring. It also outlines the unique capabilities of magnetic relaxometry relative to MRI, ultrasound, X-ray imaging, blood biomarkers, and biopsies.
Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent
November 5, 2025
FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and